Interview with Danielle Roberts, PA-C: Onboarding APPs New to Multiple Myeloma Practice

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Evolving Technology and Monitoring of Disease

Interview with Dennis Verducci, MSN, RN, NP-BC, OCN: Real-World Treatment and Transplant Strategies

Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

A Review of Unmet Needs and Ways to Provide Optimal Care in Multiple Myeloma

A Focus on Relapsed Multiple Myeloma

Ethical Challenges in CAR-T Slot Allocation

Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management

Journal of Cancer Policy

Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

Cancer Metastasis Reviews

CAR T-cell therapy to treat multiple myeloma: Current state and future directions

Blood Advances

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Journal of Patient-Reported Outcomes

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

European Journal of Haematology

Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry

Leukemia

LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Multiple Myeloma Resource Center